Akebia Therapeutics, Inc. (AKBA): debt financing — Akebia draws $8.0M Tranche B from Kreos loan facility; $10.0M Tranche C still available

Akebia Therapeutics, Inc.

Akebia drew $8.0M Tranche B loan on April 17, 2024, netting $7.5M after debt issuance costs and fees.
Remaining borrowing capacity under Tranche C is $10.0M, available through December 31, 2024.
Total facility remains $55M; initial $37M tranche was funded on January 29, 2024.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Akebia Therapeutics, Inc. incurred term loan of $8.0 million with Kreos Capital VII (UK) Limited, which are funds and accounts managed by BlackRock Inc..

Instrument: term loan
Principal: $8.0 million
Counterparty: Kreos Capital VII (UK) Limited, which are funds and accounts managed by BlackRock Inc.
Event: incurrence

Exact text from the filing

tranche of $37.0 million, which was funded on the Closing Date. In addition to the initial tranche, the Term Loan Facility included additional tranches available as follows: $8.0 million available in a single draw through December 31, 2024 (the “Tranche B Loan”), and $10.0 million available in a single draw through December 31, 2024 (the “Tranche C Loan”). On

View on SEC.gov

305 debt financings filed in the last 30 days. Browse all debt financings →

Akebia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001517022-24-000035

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.